Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics and Malpractice Statement

AI policies

Indexing and Abstracting

Peer Review Process

Journal Metrics

Pregnancy outcome in patients with multiple sclerosis: A retrospective study from single center in Benghazi, Libya

Articles in Press

Document Type : Original Article

Authors

1 Department of Internal Medicine, Neurology Unit, Multiple Sclerosis Clinic, Benghazi Medical Center, Benghazi, Libya Department of Medicine, School of Medicine, University of Benghazi, Benghazi, Libya

2 Department of Internal Medicine, Neurology Unit, Multiple Sclerosis Clinic, Benghazi Medical Center, Benghazi, Libya

Abstract

Background: Misconceptions about multiple sclerosis (MS), pregnancy, and disease-modifying therapies (DMTs) are common, often driven by fears that DMTs pose risks to the fetus or that pregnancy will exacerbate the disease. This study aimed to evaluate and document local clinical practices and decision-making processes in the management of women with MS regarding DMT use during pregnancy.
Methods: A retrospective review was conducted at the MS Clinic of Benghazi Medical Center, Benghazi, Libya, from January 1, 2016 to December 31, 2019. Medical records of women meeting the 2017 McDonald’s criteria for MS diagnosis were analyzed. Data collected included demographic and clinical variables, pregnancy outcomes, DMT use, and postpartum care. Statistical analysis was performed using SPSS software.
Results: Thirty-six women (61 pregnancies) were included. The median age was 36 years (range: 24-56). Unplanned pregnancies occurred in 24/36 women, 32/61 pregnancies (52%). Only five women continued DMTs during pregnancy. Uncomplicated pregnancies occurred in 30/36 women (83%), while postpartum relapses were reported in 12 women (33%), 11 with unplanned pregnancies. The median time to DMT resumption postpartum was 4 months. Breastfeeding was practiced for a median duration of 4 months. Preconception magnetic resonance imaging (MRI) was performed in 6 women (16.6%).
Conclusion: This study provides valuable insights into the management of MS during pregnancy in Libya. While the sample size is small, the findings underscore the importance of standardized guidelines for DMT use, pregnancy planning, and postpartum care. Future studies with larger cohorts and broader DMT options are needed.

Keywords

Main Subjects

References
  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13): 938-52.
  2. Coyle PK. What Can We Learn from Sex Differences in MS? J Pers Med 2021; 11(10).
  3. Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol 2019; 19(2): 106-14.
  4. Makkawi S, Lavorato D, Greenfield J, Parpal H, Metz L. Long term effect of delaying disease modifying therapy in patients with multiple sclerosis due to pregnancy planning. Proceedings of the 3rd MENACTRIMS Congress Conference; 2017 Nov 24-25; Dubai, UAE.
  5. Flachenecker P, Hartung HP. [Multiple sclerosis and pregnancy. Overview and status of the European multicenter PRIMS study]. Nervenarzt 1995; 66(2): 97-104.
  6. Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, et al. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol 2015; 72(10): 1132-8.
  7. Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of Women with Multiple Sclerosis Planning Pregnancy. Curr Treat Options Neurol 2021; 23(4): 11.
  8. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012; 79(11): 1130-5.
  9. Richman S, Wallace K, Liu S, Sperling B. Final Results from the AVONEX® (Intramuscular Interferon Beta-1a) Pregnancy Exposure Registry (P06.191). Neurology 2012; 78(1_supplement): P06.191.
  10. Romero RS, Lünzmann C, Bugge JP. Pregnancy outcomes in patients exposed to interferon beta-1b. J Neurol Neurosurg Psychiatry 2015; 86(5): 587-9.
  11. Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM, Jr., Albano JD, Rametta MJ. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open 2014; 4(5): e004536.
  12. Elshukri M, Elkaseh K, Bennour AM, El-Zawawi HA. Characteristics of Patients with Newly Diagnosed Multiple Sclerosis–A 5-year Study at Benghazi Medical Center, Benghazi, Libya. APIK J Intern Med 2025; 13(1): 45-9.
  13. Radhakrishnan K, Ashok PP, Sridharan R, Mousa ME. Prevalence and pattern of multiple sclerosis in Benghazi, north-eastern Libya. J Neurol Sci 1985; 70(1): 39-46.
  14. El-Zawawi HA, Zoubi S. Prevalence and pattern of multiple sclerosis in Benghazi Libya. J Neurol Sci 2019; 405: 33.
  15. Bennour AM, Elshukri M, Amer N, Elzawawi H, Elsahli R, Elzawawi A. Multiple Sclerosis During Pregnancy: Data from the MS Clinic in Benghazi Medical Center. Mult Scler Relat Disord 2022; 59: 103581.
  16. Khan E, Kagzi Y, Elkhooly M, Surpur S, Wen S, Sharma K, et al. Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol 2023; 383: 578178.
  17. Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, et al. The Italian multiple sclerosis register. Neurol Sci 2019; 40(1): 155-65.
  18. Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012; 12: 124.
  19. Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler 2016; 22(6): 810-6.
  20. Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, et al. Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. Int J MS Care 2018; 20(1): 9-14.
  21. Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health 2018; 6(4): e380-e9.
  22. Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 2014; 124(6): 1157-68.
  23. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler 2013; 19(7): 835-43.
  24. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases 2015; 3(7): 545-55.
  25. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90(17): 777-88.
  26. Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018; 90(10): e840-e6.
  27. Villaverde-González R, Candeliere-Merlicco A, Alonso-Frías MA, Aparicio Castro E, Carrillo Alcaraz A, Mallada Frechín J, et al. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study. Mult Scler Relat Disord 2020; 46: 102518.
  28. Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, et al. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology 2021; 96(24): e2989-e3002.
  29. Varytė G, Arlauskienė A, Ramašauskaitė D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol 2021; 33(5): 378-83.
  30. Graham EL, Bove R, Costello K, Crayton H, Jacobs DA, Shah S, et al. Practical Considerations for Managing Pregnancy in Patients With Multiple Sclerosis: Dispelling the Myths. Neurol Clin Pract 2024; 14(2): e200253.
  31. Alroughani R, Inshasi J, Al-Asmi A, Alqallaf A, Al Salti A, Shatila A, et al. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Postgrad Med 2020; 132(4): 368-76.
  32. Alroughani R, Inshasi JS, Deleu D, Al-Hashel J, Shakra M, Elalamy OR, et al. An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. Neurol Ther 2019; 8(1): 13-23.
  33. McCombe PA. The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Clin Med 2018; 7(12).
  34. Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014; 20(6): 739-46.
  35. Langer-Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66(8): 958-63.
  36. Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med 2012; 7(2): 123-5.
  37. Ciplea AI, Langer-Gould A, Stahl A, Thiel S, Queisser-Wahrendorf A, Gold R, et al. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm 2020; 7(4).
  38. Essilfie P. Multiple Sclerosis in Pregnancy—A Practical Guide for the Obstetrician. Open J Obstet Gynecol 2020; 10(9): 1307-14.
  39. Lum M, Tsiouris AJ. MRI safety considerations during pregnancy. Clin Imaging 2020; 62: 69-75.
  40. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. Jama 2016; 316(9): 952-61.
Current Journal of Neurology

Articles in Press, Accepted Manuscript
Available Online from 17 August 2025
Files
Share
How to cite
Statistics